Trade KalVista Pharmaceuticals, Inc. - KALV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Kalvista Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 11.03 |
Open* | 10.93 |
1-Year Change* | 66.36% |
Day's Range* | 10.93 - 12.37 |
52 wk Range | 6.26-13.37 |
Average Volume (10 days) | 423.68K |
Average Volume (3 months) | 6.84M |
Market Cap | 430.60M |
P/E Ratio | -100.00K |
Shares Outstanding | 34.56M |
Revenue | N/A |
EPS | -3.06 |
Dividend (Yield %) | N/A |
Beta | 0.96 |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 11.03 | -0.15 | -1.34% | 11.18 | 11.36 | 10.95 |
Mar 26, 2024 | 11.08 | -0.10 | -0.89% | 11.18 | 11.25 | 10.68 |
Mar 25, 2024 | 11.10 | -0.57 | -4.88% | 11.67 | 11.80 | 11.09 |
Mar 22, 2024 | 11.81 | -0.17 | -1.42% | 11.98 | 12.22 | 11.70 |
Mar 21, 2024 | 12.11 | 0.04 | 0.33% | 12.07 | 12.62 | 12.01 |
Mar 20, 2024 | 12.18 | 0.37 | 3.13% | 11.81 | 12.20 | 11.67 |
Mar 19, 2024 | 11.79 | 0.03 | 0.26% | 11.76 | 12.31 | 11.56 |
Mar 18, 2024 | 11.96 | 0.30 | 2.57% | 11.66 | 12.30 | 11.55 |
Mar 15, 2024 | 11.90 | -0.34 | -2.78% | 12.24 | 12.40 | 11.84 |
Mar 14, 2024 | 12.40 | 0.31 | 2.56% | 12.09 | 12.53 | 12.05 |
Mar 13, 2024 | 12.47 | 0.15 | 1.22% | 12.32 | 12.72 | 12.32 |
Mar 12, 2024 | 12.46 | -0.32 | -2.50% | 12.78 | 12.94 | 12.26 |
Mar 11, 2024 | 13.07 | -0.90 | -6.44% | 13.97 | 14.31 | 13.03 |
Mar 8, 2024 | 14.32 | 0.47 | 3.39% | 13.85 | 14.49 | 13.69 |
Mar 7, 2024 | 13.97 | 0.19 | 1.38% | 13.78 | 14.03 | 12.79 |
Mar 6, 2024 | 14.35 | 0.47 | 3.39% | 13.88 | 14.56 | 13.88 |
Mar 5, 2024 | 13.95 | 0.18 | 1.31% | 13.77 | 14.17 | 13.77 |
Mar 4, 2024 | 14.01 | -0.10 | -0.71% | 14.11 | 14.17 | 13.77 |
Mar 1, 2024 | 14.11 | 0.47 | 3.45% | 13.64 | 14.22 | 13.63 |
Feb 29, 2024 | 13.60 | 0.24 | 1.80% | 13.36 | 13.76 | 13.36 |
KalVista Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, July 5, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2024 Kalvista Pharmaceuticals Inc Earnings Release Q4 2024 Kalvista Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 12.69 | 16.127 |
Revenue | 0 | 0 | 0 | 12.69 | 16.127 |
Total Operating Expense | 110.871 | 96.613 | 57.923 | 53.223 | 45.947 |
Selling/General/Admin. Expenses, Total | 30.595 | 26.446 | 16.637 | 13.029 | 10.926 |
Research & Development | 80.276 | 70.167 | 41.286 | 40.194 | 35.021 |
Operating Income | -110.871 | -96.613 | -57.923 | -40.533 | -29.82 |
Interest Income (Expense), Net Non-Operating | 2.183 | 0.153 | 1.95 | 1.763 | 1.498 |
Other, Net | 15.781 | 14.121 | 9.729 | 9.53 | 7.63 |
Net Income Before Taxes | -92.907 | -82.339 | -46.244 | -29.24 | -20.692 |
Net Income After Taxes | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Net Income Before Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Net Income | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Income Available to Common Excl. Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Income Available to Common Incl. Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Diluted Net Income | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
Diluted Weighted Average Shares | 27.8909 | 24.4731 | 19.0944 | 17.7487 | 15.0809 |
Diluted EPS Excluding Extraordinary Items | -3.33109 | -3.36447 | -2.42186 | -1.64046 | -1.38029 |
Diluted Normalized EPS | -3.33109 | -3.36447 | -2.42186 | -1.64046 | -1.38029 |
Dividends per Share - Common Stock Primary Issue |
Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 31.728 | 26.945 | 25.883 | 26.316 | 26.811 |
Selling/General/Admin. Expenses, Total | 7.777 | 6.882 | 7.806 | 8.13 | 7.598 |
Research & Development | 23.951 | 20.063 | 18.077 | 18.186 | 19.213 |
Operating Income | -31.728 | -26.945 | -25.883 | -26.316 | -26.811 |
Interest Income (Expense), Net Non-Operating | 1.135 | 1.329 | 0.132 | -0.275 | -0.74 |
Other, Net | 4.288 | 4.313 | 3.494 | 3.549 | 3.438 |
Net Income Before Taxes | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Net Income After Taxes | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Net Income Before Extra. Items | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Net Income | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Income Available to Common Excl. Extra. Items | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Income Available to Common Incl. Extra. Items | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Diluted Net Income | -26.305 | -21.303 | -22.257 | -23.042 | -24.113 |
Diluted Weighted Average Shares | 34.1323 | 28.2785 | 24.595 | 24.5576 | 24.543 |
Diluted EPS Excluding Extraordinary Items | -0.77068 | -0.75333 | -0.90494 | -0.93828 | -0.98248 |
Diluted Normalized EPS | -0.77068 | -0.75333 | -0.90494 | -0.93828 | -0.98248 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total Current Assets | 172.326 | 193.647 | 264.264 | 88.696 | 115.546 |
Cash and Short Term Investments | 149.375 | 166.202 | 248.929 | 67.714 | 100.811 |
Cash & Equivalents | 56.238 | 30.732 | 50.592 | 15.789 | 32.006 |
Total Receivables, Net | 18.644 | 14.098 | 10.418 | 16.527 | 11.315 |
Prepaid Expenses | 4.307 | 13.347 | 4.917 | 4.455 | 3.42 |
Total Assets | 183.202 | 203.88 | 272.013 | 92.529 | 118.132 |
Property/Plant/Equipment, Total - Net | 10.77 | 10.04 | 7.549 | 3.655 | 2.413 |
Total Current Liabilities | 15.032 | 11.576 | 9.774 | 7.72 | 18.052 |
Accounts Payable | 4.817 | 3.638 | 1.981 | 1.677 | 2.86 |
Accrued Expenses | 10.215 | 7.938 | 7.793 | 6.043 | 5.593 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 9.545 | |||
Total Liabilities | 22.177 | 18.787 | 14.82 | 8.777 | 21.394 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 161.025 | 185.093 | 257.193 | 83.752 | 96.738 |
Redeemable Preferred Stock | |||||
Common Stock | 0.034 | 0.025 | 0.024 | 0.018 | 0.017 |
Additional Paid-In Capital | 507.133 | 439.104 | 426.437 | 207.208 | 191.123 |
Retained Earnings (Accumulated Deficit) | -343.082 | -250.175 | -167.836 | -121.592 | -92.476 |
Other Equity, Total | -3.06 | -3.861 | -1.432 | -1.882 | -1.926 |
Total Liabilities & Shareholders’ Equity | 183.202 | 203.88 | 272.013 | 92.529 | 118.132 |
Total Common Shares Outstanding | 34.1711 | 24.5508 | 24.4225 | 17.8456 | 17.2778 |
Other Long Term Assets, Total | 0.106 | 0.193 | 0.2 | 0.178 | 0.173 |
Current Port. of LT Debt/Capital Leases | 0.054 | ||||
Capital Lease Obligations | 0 | ||||
Other Liabilities, Total | 7.145 | 7.211 | 5.046 | 1.057 | 3.342 |
Short Term Investments | 93.137 | 135.47 | 198.337 | 51.925 | 68.805 |
Property/Plant/Equipment, Total - Gross | 13.728 | 12.459 | 9.638 | 5.023 | 3.309 |
Accumulated Depreciation, Total | -2.958 | -2.419 | -2.089 | -1.368 | -0.896 |
Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
---|---|---|---|---|---|
Total Current Assets | 149.842 | 172.326 | 192.133 | 151.216 | 170.407 |
Cash and Short Term Investments | 123.257 | 149.375 | 171.685 | 122.273 | 142.075 |
Cash & Equivalents | 49.409 | 56.238 | 85.049 | 38.585 | 37.863 |
Short Term Investments | 73.848 | 93.137 | 86.636 | 83.688 | 104.212 |
Total Receivables, Net | 20.57 | 18.644 | 12.681 | 21.93 | 19.289 |
Prepaid Expenses | 6.015 | 4.307 | 7.767 | 7.013 | 9.043 |
Total Assets | 160.332 | 183.202 | 203.468 | 162.838 | 182.319 |
Property/Plant/Equipment, Total - Net | 10.384 | 10.77 | 11.138 | 11.425 | 11.694 |
Other Long Term Assets, Total | 0.106 | 0.106 | 0.197 | 0.197 | 0.218 |
Total Current Liabilities | 14.132 | 15.032 | 11.606 | 11.32 | 9.733 |
Accounts Payable | 5.06 | 4.817 | 1.698 | 3.384 | 2.908 |
Accrued Expenses | 9.072 | 10.215 | 9.908 | 7.936 | 6.825 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20.997 | 22.177 | 19.027 | 19.025 | 17.747 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 6.865 | 7.145 | 7.421 | 7.705 | 8.014 |
Total Equity | 139.335 | 161.025 | 184.441 | 143.813 | 164.572 |
Common Stock | 0.034 | 0.034 | 0.034 | 0.025 | 0.025 |
Additional Paid-In Capital | 510.591 | 507.133 | 504.725 | 444.588 | 441.914 |
Retained Earnings (Accumulated Deficit) | -368.399 | -343.082 | -316.777 | -295.474 | -273.217 |
Other Equity, Total | -2.891 | -3.06 | -3.541 | -5.326 | -4.15 |
Total Liabilities & Shareholders’ Equity | 160.332 | 183.202 | 203.468 | 162.838 | 182.319 |
Total Common Shares Outstanding | 34.2666 | 34.1711 | 34.1278 | 24.602 | 24.5709 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -82.339 | -46.244 | -29.116 | -20.816 | -15.805 |
Cash From Operating Activities | -78.134 | -30.171 | -44.816 | -36.365 | 10.558 |
Cash From Operating Activities | 0.564 | 0.537 | 0.512 | 0.378 | 0.18 |
Non-Cash Items | 15.963 | 7.19 | 4.428 | 2.863 | 0.409 |
Cash Interest Paid | |||||
Changes in Working Capital | -12.322 | 8.346 | -20.64 | -18.79 | 25.774 |
Cash From Investing Activities | 57.86 | -147.654 | 16.753 | -69.422 | -1.427 |
Capital Expenditures | -0.931 | -0.082 | -0.22 | -1.081 | -1.427 |
Other Investing Cash Flow Items, Total | 58.791 | -147.572 | 16.973 | -68.341 | 0 |
Cash From Financing Activities | 1.581 | 212.117 | 11.584 | 87.943 | 8.986 |
Issuance (Retirement) of Stock, Net | 1.581 | 212.117 | 11.638 | 88.152 | 9.137 |
Foreign Exchange Effects | -1.167 | 0.511 | 0.262 | -1.205 | 1.988 |
Net Change in Cash | -19.86 | 34.803 | -16.217 | -19.049 | 20.105 |
Issuance (Retirement) of Debt, Net | 0 | -0.054 | -0.209 | -0.151 |
Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -66.602 | -45.299 | -23.042 | -82.339 | -58.226 |
Cash From Operating Activities | -52.625 | -43.336 | -22.742 | -78.134 | -51.345 |
Cash From Operating Activities | 0.53 | 0.331 | 0.158 | 0.564 | 0.408 |
Non-Cash Items | 7.168 | 5.214 | 3.498 | 15.963 | 11.66 |
Changes in Working Capital | 6.279 | -3.582 | -3.356 | -12.322 | -5.187 |
Cash From Investing Activities | 47.625 | 50.142 | 30.044 | 57.86 | 45.426 |
Capital Expenditures | -1.127 | -1.112 | -0.92 | -0.931 | -0.845 |
Other Investing Cash Flow Items, Total | 48.752 | 51.254 | 30.964 | 58.791 | 46.271 |
Cash From Financing Activities | 58.149 | 0.336 | 0.168 | 1.581 | 1.443 |
Issuance (Retirement) of Stock, Net | 58.149 | 0.336 | 0.168 | 1.581 | 1.443 |
Foreign Exchange Effects | 1.168 | 0.711 | -0.339 | -1.167 | -0.539 |
Net Change in Cash | 54.317 | 7.853 | 7.131 | -19.86 | -5.015 |
Issuance (Retirement) of Debt, Net | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
KalVista Pharmaceuticals, Inc. Company profile
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.
Industry: | Biopharmaceuticals |
55 Cambridge Pkwy Ste 901E
CAMBRIDGE
MASSACHUSETTS 02142-1234
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com